Outcomes of SGLT2 inhibitors after transcatheter mitral valve repair in patients with type 2 diabetes mellitus

More on SGLT2 inhibitors

• Orforglipron matches insulin glargine on cardiovascular safety

  Lancet · 4 Oct 2026

• SGLT2 inhibitors raise genital but not urinary infection risk

  Clinical Pharmacology and Therapeutics · 4 Oct 2026

• SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

  Diabetes & Vascular Disease Research · 4 Oct 2026

• Low-carb telemedicine links to fewer cardiovascular events

  Cardiology and Therapy · 4 Oct 2026